Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Eli Lilly and Company (LLY : NYSE)
 
 • Company Description   
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.

Number of Employees: 35,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $298.85 Daily Weekly Monthly
20 Day Moving Average: 3,023,784 shares
Shares Outstanding: 950.16 (millions)
Market Capitalization: $283,955.19 (millions)
Beta: 0.40
52 Week High: $314.00
52 Week Low: $195.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 7.22% 17.40%
12 Week 19.14% 33.89%
Year To Date 8.19% 32.18%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
LILLY CORPORATE CTR
-
INDIANAPOLIS,IN 46285
USA
ph: 317-276-2000
fax: 317-276-4878
johnson_philip_l@lilly.com http://www.lilly.com
 
 • General Corporate Information   
Officers
David A. Ricks - Chief Executive Officer; Chair and President
Anat Ashkenazi - Chief Financial Officer and Senior Vice President
Donald A. Zakrowski - Vice President; Finance; and Chief Accounting Offi
Ralph Alvarez - Director
Katherine Baicker - Director

Peer Information
Eli Lilly and Company (AGN.)
Eli Lilly and Company (ABBV)
Eli Lilly and Company (NVO)
Eli Lilly and Company (LLY)
Eli Lilly and Company (RHHBY)
Eli Lilly and Company (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 532457108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/02/22
Share - Related Items
Shares Outstanding: 950.16
Most Recent Split Date: 10.00 (2.00:1)
Beta: 0.40
Market Capitalization: $283,955.19 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 1.31%
Current Fiscal Quarter EPS Consensus Estimate: $1.93 Indicated Annual Dividend: $3.92
Current Fiscal Year EPS Consensus Estimate: $8.25 Payout Ratio: 0.44
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: -0.01
Estmated Long-Term EPS Growth Rate: 15.32% Last Dividend Paid: 05/13/2022 - $0.98
Next EPS Report Date: 08/02/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 36.24
Trailing 12 Months: 33.50
PEG Ratio: 2.36
Price Ratios
Price/Book: 30.01
Price/Cash Flow: 31.82
Price / Sales: 9.68
EPS Growth
vs. Year Ago Period: 40.11%
vs. Previous Quarter: 5.22%
Sales Growth
vs. Year Ago Period: 14.76%
vs. Previous Quarter: -2.37%
ROE
03/31/22 - 97.58
12/31/21 - 96.36
09/30/21 - 111.51
ROA
03/31/22 - 16.92
12/31/21 - 15.52
09/30/21 - 16.21
Current Ratio
03/31/22 - 1.27
12/31/21 - 1.23
09/30/21 - 1.30
Quick Ratio
03/31/22 - 0.98
12/31/21 - 0.97
09/30/21 - 1.02
Operating Margin
03/31/22 - 27.65
12/31/21 - 26.26
09/30/21 - 27.66
Net Margin
03/31/22 - 20.90
12/31/21 - 19.71
09/30/21 - 21.52
Pre-Tax Margin
03/31/22 - 22.96
12/31/21 - 21.74
09/30/21 - 24.44
Book Value
03/31/22 - 9.96
12/31/21 - 9.57
09/30/21 - 8.31
Inventory Turnover
03/31/22 - 1.94
12/31/21 - 1.91
09/30/21 - 1.82
Debt-to-Equity
03/31/22 - 1.60
12/31/21 - 1.68
09/30/21 - 1.95
Debt-to-Capital
03/31/22 - 61.56
12/31/21 - 62.63
09/30/21 - 66.12
 

Powered by Zacks Investment Research ©